Insurance barriers and distribution challenges are marring the rollout of highly anticipated new shots to protect babies from respiratory syncytial virus (RSV) and young kids from COVID-19, drawing anger and frustration from parents and pediatricians.
Medical practices don’t know when, or how much, they will get paid for the pricey RSV shot, and they are struggling to find workarounds.
For the updated COVID-19 vaccine, parents are finding availability is ...